Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Phase III Clinical Study Comparing the Efficacy and Safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol Versus FOSTER® in Patients With Asthma.

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

A multicenter, randomized, double-blind, active-controlled, parallel-group Phase III clinical study comparing the efficacy and safety of Beclometasone Dipropionate and Formoterol Inhalation Aerosol versus FOSTER® in patients with asthma. The purpose of this study is to compare the efficacy and safety of the Beclomethasone Dipropionate and Formoterol Fumarate inhalation aerosol (manufactured by Lunan Better Pharmaceutical Co., Ltd.) with FOSTER® in the treatment of patients with asthma.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Male or female aged ≥18 and ≤75 years.

• Clinically diagnosed with bronchial asthma for at least 3 months at screening (with traceable diagnostic evidence and medical records), and the diagnosis has been confirmed according to the Guidelines for the Prevention and Management of Bronchial Asthma, meeting the following criteria:

• a) Positive objective test for variable airflow limitation (i.e., meeting any one of the following): (i) Positive bronchodilator reversibility test (i.e., an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from pre-bronchodilator values after inhalation of a bronchodilator; or an increase in FEV₁ of ≥12% and an absolute increase of ≥200 mL from baseline after 4 weeks of anti-inflammatory therapy with an inhaled corticosteroid, excluding respiratory tract infections); or (ii) Positive bronchial provocation test: commonly using methacholine or histamine as the inhaled provocative agent, with a positive result defined as a ≥20% decrease in FEV₁ after inhalation, indicating airway hyperresponsiveness. (A positive result from any confirmed objective test for variable airflow limitation performed within 1 year prior to signing the ICF is acceptable; if not available, a positive bronchial provocation or bronchodilator reversibility test must be met at screening.) b) Pulmonary function test: FEV₁ ≥40% of predicted value.

• Within at least 4 weeks prior to signing the ICF, the subject has been on a stable daily dose of an inhaled corticosteroid (ICS) with as-needed short-acting β₂-agonist (SABA) use but asthma is not well controlled (ACQ-5 ≥1.00), OR has been on a stable daily dose of an ICS plus a long-acting β₂-agonist (LABA) and asthma is well controlled (ACQ-5 \<1.00).

• Subjects who use SABA or other reliever medications as needed before screening may be enrolled only if the investigator assesses that they can be switched to the unified rescue medication provided in this study.

• Willing and able to comply with the protocol requirements and the investigator's instructions for pulmonary function tests, and, after training, able to correctly use the pressurized metered-dose inhaler (pMDI), peak flow meter, and complete the diary card records.

• Willing to voluntarily participate in this study and sign the informed consent form after full informed consent.

Locations
Other Locations
China
Zhongshan Hospital, Fudan University
RECRUITING
Shanghai
Contact Information
Primary
Mei Ling Jin
MLjin118@163.com
021-31587861
Backup
Zhenju Song
Song.zhenju@zs-hospital.sh.cn
021-31587861
Time Frame
Start Date: 2026-06-08
Estimated Completion Date: 2028-06
Participants
Target number of participants: 416
Treatments
Experimental: Beclometasone Dipropionate and Formoterol Inhalation Aerosol
Each canister contains 120 actuations. Each actuation delivers 100 μg of beclomethasone dipropionate and 6 μg of formoterol fumarate.
Active_comparator: FOSTER®
Each canister contains 120 actuations. Each actuation delivers 100 μg of beclomethasone dipropionate and 6 μg of formoterol fumarate.
Related Therapeutic Areas
Sponsors
Leads: Lunan Better Pharmaceutical Co., LTD.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials